Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer

Publikation: Bidrag til tidsskriftReviewpeer review

DOI

  1. A double negative: culture-negative infective endocarditis

    Publikation: Bidrag til tidsskriftLederpeer review

  2. Accelerated and personalized therapy for heart failure with reduced ejection fraction

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  3. The European Heart Journal: fulfilling the mission

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  1. Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  • Christian Lewinter
  • Torsten Holm Nielsen
  • Lars Robert Edfors
  • Cecilia Linde
  • John Martin Bland
  • M LeWinter
  • John G F Cleland
  • Lars Køber
  • Frieder Braunschweig
  • Agneta Mansson-Broberg
Vis graf over relationer

AIMS: Trastuzumab and anthracyclines, often used in the treatment of breast cancer, may impair myocardial function, and reduce left ventricular ejection fraction (LVEF), potentially causing heart failure. Randomized controlled trials (RCTs) have evaluated the effects of beta-blockers (BBs), angiotensin receptor blockers (ARBs), and angiotensin-converting enzyme inhibitors (ACEI) on trastuzumab- and anthracycline-associated cardiotoxicity. We report a meta-analysis of these RCTs in patients with breast cancer.

METHODS AND RESULTS: The primary analysis was on the effect of BBs and ACEI/ARBs on LVEF in patients treated with either trastuzumab or anthracyclines. A secondary analysis was done investigating the effect of BBs or ACEI/ARBs on LVEF in trastuzumab and anthracycline treatments. Only RCTs were included using the search term 'ARBs, ACEIs, BBs, anthracyclines, trastuzumab, and breast cancer' in PubMed, Embase, and CENTRAL up to 31 March 2021. A meta-analysis was conducted to estimate the mean difference (MD) in LVEF between intervention and placebo groups at follow-up. A total of nine RCTs (n = 1362) were included in the analysis. All patients were women. BBs and ACEI/ARBs were shown to attenuate the decline in LVEF during trastuzumab and anthracycline treatments [MD: 2.4; 95% confidence interval (CI): 0.3-4.2 and MD: 1.5; 95% CI: -0.6 to 3.7]. Compared with placebo, LVEF was significantly higher in patients assigned to BB or ACEI/ARB on trastuzumab (MD: 2.3; 95% CI: 0.0-4.6) but not on anthracyclines (MD: 1.9; 95% CI: -0.5 to 4.2).

CONCLUSION: Both BB and ACEI/ARB therapies were associated with the preservation of LVEF during trastuzumab and anthracycline-containing regimens as compared with placebo, suggesting both to be beneficial.

OriginalsprogEngelsk
TidsskriftEuropean Heart Journal
Vol/bind43
Udgave nummer27
Sider (fra-til)2562-2569
Antal sider8
ISSN0195-668X
DOI
StatusUdgivet - 14 jul. 2022

Bibliografisk note

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.

ID: 70121004